Before recommending a vaccine for use, it should be tested in labs. This procedure can take many years. FDA uses the information from these tests to agree whether to test the vaccine with people or not.
Regulatory bodies like the FDA meticulously review data from these trials before granting authorization for public use. Monitoring continues post-approval to track any adverse effects and maintain safety standards.Efficacy measures the vaccine's ability to prevent disease under ideal conditions, while safety ensures its minimal side effects.
Throughout a clinical trial, a vaccine should be tested on people who agree to get vaccinated. The Clinical trials start with 20 - 100 volunteers, but ultimately include thousands of volunteers. These tests take so many years and answer important questions like:
Adverse effect (medicine): An adverse effect is an unwanted harmful effect resulting from an intervention or other medication, such as surgery. An adverse effect also called as a "side effect", when judged to be secondary to a main or therapeutic effect.
Adverse drug reaction: An adverse drug reaction (ADR) can be defined as an unwanted or an unappreciated harmful reaction resulting from an intervention related to the use of a medicinal product. Adverse effects usually predict dangerous from future administration and warrant prevention, or alteration of the dosage regimen, or specific treatment or withdrawal of the product.
Artificial induction of immunity: The process of artificial induction of immunity enhances people immunity to a specific disorder by means other than waiting for them to catch the disease. The aim is to decrease the risk of death and suffering. Artificially acquired active immunity can be introduced to our body by a vaccine, a drug that contains the antigen. It will encourage the response against the antigen without causing symptoms of the disease.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States